Humanwell Healthcare (Group) Co. Ltd. has identified cyclopeptides reported to be useful for the treatment of Acinetobacter infections, particularly A. baumannii infections.
Researchers at GSK plc and University of Dundee have identified heterocyclic compounds reported to be potentially useful for the treatment of tuberculosis.
University of Washington has divulged compounds acting as methionyl-tRNA synthetase (bacterial) inhibitors reported to be useful for the treatment of bacterial and protozoal infections.
Antimicrobial peptides, existing in animals and plants, are the first line of defense of the organisms against bacteria. Thymol and carvacrol are two monoterpenoids with known antibacterial activity exerted through bacterial cell membrane structural disruption, which contributes to a lower risk of developing resistance compared to antibiotics acting against specific targets on cells.
Researchers at Centre Hospitalier Universitaire de Grenoble Alpes, Centre National de la Recherche Scientifique, Commissariat à l’Energie Atomique, Institut National de la Santé et de la Recherche Médicale, Université Grenoble Alpes and Université Libre de Bruxelles have synthesized calix[4]arene compounds reported to be useful for treatment of cancer, metastatic cancer, and bacterial, viral, fungal and parasitic infections.
Scientists from Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have identified UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) (bacterial) inhibitors reported to be useful for the treatment gram-negative bacterial infections.
Precisio Biotix Therapeutics Inc. has entered into an agreement with Mayo Clinic that will include co-development of novel precision antibacterials targeting indications prone to antimicrobial-resistant (AMR) infections. Precisio creates lower cost novel precision biological antibacterials with a focus on lung and skin infections.
Blacksmith Medicines Inc. has disclosed UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) (bacterial) inhibitors reported to be useful for the treatment of Pseudomonas aeruginosa infection.
